Abbott Laboratories

ABT · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$655K – $6.7M 31 disclosures · 18 bought / 13 sold · last Aug 26, 2026
Ro Khanna D · HOUSE · CA	−$683K – $1.1M −$677K – $1.2M today 84 filings · last Jun 30, 2026
K. Michael Conaway R · HOUSE · TX	$15K – $184K −$52K – $236K today 5 filings · last Sep 28, 2020
Carol D. Miller R · HOUSE · WV	$16K – $65K $16K – $65K today 2 filings · last Mar 4, 2021
Pete Sessions R · HOUSE · TX	$16K – $65K $32K – $129K today 2 filings · last May 2, 2018
Thomas J. Rooney R · HOUSE · FL	$16K – $65K $25K – $113K today 2 filings · last Nov 5, 2018
Dean Phillips D · HOUSE · MN	$5K – $75K $6K – $87K today 5 filings · last Jan 5, 2021
David B. McKinley R · HOUSE · WV	−$13K – $78K −$4K – $113K today 5 filings · last Sep 21, 2022
Thomas H. Kean, Jr. R · HOUSE · NJ	$4K – $60K $4K – $56K today 4 filings · last Jan 29, 2026
Shelley Moore Capito R · SENATE · WV	−$10K – $74K −$2K – $138K today 6 filings · last Feb 24, 2025

Recent transactions

Trades from Mar 6, 2026 – Sep 18, 2026

Politician	Type	Filed after	Amount
Gilbert Ray Cisneros, Jr. D · HOUSE · CA-31	Buy	24 days Sep 18, 2026 → Oct 12, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	43 days Aug 26, 2026 → Oct 8, 2026	≥$15K
Donald Trump R · EXECUTIVE	Buy	48 days Aug 21, 2026 → Oct 8, 2026	≥$1.0M
Donald Trump R · EXECUTIVE	Buy	52 days Aug 17, 2026 → Oct 8, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	53 days Jul 31, 2026 → Sep 22, 2026	≥$100K
Donald Trump R · EXECUTIVE	Sell	67 days Jul 17, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	76 days Jul 8, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	59 days Jun 24, 2026 → Aug 22, 2026	≥$100K
Donald Trump R · EXECUTIVE	Sell	60 days Jun 23, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	61 days Jun 22, 2026 → Aug 22, 2026	≥$500K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

3,076

13F shares

1.44B

Total invested

$131B

Ownership

82.3%

New positions

191

Closed positions

326

Increased positions

1,252

Reduced positions

1,405

Put/Call ratio

0.99

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	152.6M	$13.8B	+4.72%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	113.8M	$10.3B	+0.71%
STATE STREET CORP	9/22/2026	80.9M	$7.3B	+1.70%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	59.7M	$5.4B	+31.15%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	59.7M	$5.4B	—
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	49M	$4.4B	+2.24%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	39.2M	$3.5B	+0.18%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	36.9M	$3.3B	−25.85%
CAPITAL INTERNATIONAL INVESTORS	8/12/2026	34.7M	$3.1B	−7.58%
MORGAN STANLEY	8/13/2026	26.6M	$2.4B	−11.60%
NORGES BANK	8/12/2026	23.4M	$2.1B	—
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	22.8M	$2.1B	+31.89%
FRANKLIN RESOURCES INC	8/13/2026	18.8M	$1.7B	−6.07%
NORTHERN TRUST CORP	8/13/2026	18.3M	$1.7B	−5.78%
BANK OF AMERICA CORP /DE/	8/14/2026	17.7M	$1.6B	−8.34%
GOLDMAN SACHS GROUP INC	8/14/2026	16.8M	$1.5B	+15.55%
DEUTSCHE BANK AG\	8/7/2026	16.7M	$1.5B	+18.56%
JPMORGAN CHASE & CO	8/12/2026	15.1M	$1.4B	−43.60%
WELLS FARGO & COMPANY/MN	8/14/2026	15.2M	$1.4B	−4.60%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	8/12/2026	13.6M	$1.2B	+0.00%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	13.4M	$1.2B	−13.81%
FMR LLC	8/13/2026	13.4M	$1.2B	+23.77%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	12.8M	$1.2B	−2.75%
LEGAL & GENERAL GROUP PLC	8/14/2026	11.9M	$1.1B	−2.89%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	10.9M	$988.8M	+97.33%

Insider transactions

Insider	Type	Transacted	Price	Date
Ahuja Nita	A-AWARD	318	—	Sep 30
Roman Michael F	A-AWARD	381	—	Sep 30
Conroy Kevin T	A-AWARD	318	—	Sep 30
Gonzalez Patricia Paola	A-AWARD	333	—	Sep 30
Stratton John G	A-AWARD	397	—	Sep 30
Conroy Kevin T	F-INKIND	52.5K	$103.99	Sep 23
Mccoy John A. Jr.	S-SALE	27	$109.54	Sep 2
Mccoy John A. Jr.	F-INKIND	52	$110.36	Sep 1
Boudreau Philip P	F-INKIND	388	$110.36	Sep 1
Ford Robert B	M-EXEMPT	151.9K	$44.40	Aug 25

Analyst consensus

Buy43 analysts

Bearish · 0 · Hold · 9 · Bullish · 34

Earnings history

	EPS	Estimate
Q4 2024	$1.34	$1.34	Match
Q1 2025	$1.09	$1.07	Beat
Q2 2025	$1.26	$1.26	Match
Q3 2025	$1.30	$1.30	Match
Q4 2025	$1.50	$1.50	Match
Q1 2026	$1.15	$1.14	Beat
Q2 2026	$1.31	$1.28	Beat
Q3 2026	$1.42	$1.42	Match

Peers

Company overview

IPO dateMar 17, 1980

CEORobert Ford

Employees115,000

SectorHealthcare

IndustryMedical - Devices

CountryUS

ExchangeNew York Stock Exchange

Websitewww.abbott.com

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.